Breast Cancer Clinical Trial
Official title:
Acupuncture and Aromatase Inhibitor Related Arthralgia
RATIONALE: Acupuncture may help relieve moderate or severe joint pain caused by aromatase
inhibitors.
PURPOSE: This randomized phase II trial is studying acupuncture in treating women with stage
I, stage II, or stage III breast cancer with aromatase inhibitor-related joint pain.
PRIMARY OBJECTIVES:
I. To determine the overall effect of acupuncture for reducing arthralgia among breast cancer
survivors (BCS) receiving AIs.
II. To explore the specific effect of acupuncture needling for reducing arthralgia among BCS
receiving AIs.
III. To elucidate the relationship between response expectancy measured by the Acupuncture
Expectancy Scale (AES) and clinical response to acupuncture defined as percent reduction of
BPI pain severity score at the end of intervention.
SECONDARY OBJECTIVES:
I. To explore the effects of acupuncture on other common symptoms including fatigue,
insomnia, and psychological distress among BCS who experience joint pain.
II. To determine the correlation among pain and fatigue, insomnia, and psychological distress
using previously validated instruments.
III. To explore the effects of acupuncture on quality of life among BCS who experience joint
pain.
IV. To explore the effect of acupuncture on objective measure of sleep and activity.
V. To identify potential genetic determinants to response to acupuncture.
OUTLINE:
Patients are randomized to 1 of 3 treatment arms.
ARM I (Acupuncture): Patients undergo 10, 20-minute sessions of acupuncture over 8 weeks
(twice weekly for 2 weeks and 6 weekly treatments).
ARM II (Placebo): Patients undergo 10, 20-minute sessions of sham acupuncture treatments over
8 weeks (twice weekly for 2 weeks and 6 weekly treatments) via Streitberger needles at
non-acupuncture points.
ARM III (Control): Wait-list control patients are contacted by phone at the same frequency as
real and placebo acupuncture groups for data collection at weeks 1, 4, and 8.
After completion of study treatment, patients are followed at 4 weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |